Sometimes, a slide like Regeneron has experienced makes a stock a great bargain. In other cases, poor performance reflects longer-term problems. Is …
While this makes REGN appear like a stock to avoid or sell if you own it, you might change your mind after I explain the assumptions behind the P/E ratio. In this article, I will deconstruct the P/E ratio and highlight what you need to be …
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $328.49 to a high of $337.52. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $335.70 on volume of 295,000 …
Regeneron and Sanofi announced positive study results on their cholesterol-reducer over the weekend. At least as important to me, they announced a favorable cost-benefit opinion from an independent organization. This opinion favors …
The Company has also agreed to grant a limited waiver of the "lock-up" in the Amended and Restated Investor Agreement between the companies, so that Sanofi may sell up to an aggregate of 1.4 million shares of Regeneron Common …
Upcoming approvals. Regeneron's stock is undervalued by at least 10 percent and has up to 30 percent upside. In the month following Regeneron’s (REGN) fourth quarter results, the stock is mostly lower despite the company beating …